Clinical Trial

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Study acronym: LUNG-IST-127
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II study to assess the efficacy, safety, and Health Related Quality of Life (HRQoL) of combination cabozantinib and pembrolizumab as maintenance therapy for patients with metastatic squamous Non Small Cell Lung Cancer(sqNSCLC) who have received 4 cycles of induction therapy with pembrolizumab, carboplatin, and nab-paclitaxel or paclitaxel.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-11-04; most recent amendment 2026-01-06.
Status change: Not Yet Recruiting → Recruiting 2022-12-12
Trial Details
NCT Number NCT05613413
Lead Sponsor University of Illinois at Chicago
Conditions Metastatic Squamous Non-Small Cell Lung Carcinoma
Enrollment 36 participants
Start Date 2022-12-28
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-01-08